CCCC
insider transactionsC4 Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-10.0K
0 buy · 10.0K sell
Net value · 365d
-$22.2K
$0 in · $22.2K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
1
0 buy · 10.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director
$0
1.1K sh
Own New
-
Exercise·M
Director
$2.3K
1.1K sh · $2.11
Own +2%
-
Grant·A
Director
$14.5K
5.4K sh · $2.70
Own +8%
-
Grant·A
Director
$11.5K
4.3K sh · $2.70
Own +7%
-
Other·F
Andrew Hirsch KEY
President & CEO
$17.1K
9.1K sh · $1.89
Own -1%
-
Exercise·M
Andrew Hirsch KEY
President & CEO
$0
20.4K sh
Own +2%
-
Other·F
Chief Scientific Officer
$4.6K
2.4K sh · $1.89
Own -1%
-
Exercise·M
Chief Scientific Officer
$0
7.0K sh
Own +2%
-
Other·F
Chief People Officer
$13.7K
7.3K sh · $1.89
Own -2%
-
Exercise·M
Chief People Officer
$0
20.9K sh
Own +7%
-
Other·F
Andrew Hirsch KEY
President & CEO
$74.0K
39.2K sh · $1.89
Own -3%
-
Exercise·M
Andrew Hirsch KEY
President & CEO
$0
81.7K sh
Own +8%
-
Other·F
Chief Medical Officer
$31.3K
16.6K sh · $1.89
Own -4%
-
Exercise·M
Chief Medical Officer
$0
30.9K sh
Own +8%
-
Other·F
Chief Accounting Officer
$6.2K
3.3K sh · $1.89
Own -4%
-
Exercise·M
Chief Accounting Officer
$0
9.4K sh
Own +14%
-
Other·F
Chief Business Officer
$13.7K
7.3K sh · $1.89
Own -2%
-
Exercise·M
Chief Business Officer
$0
20.9K sh
Own +7%
-
Other·F
Kendra Adams KEY
Chief Financial Officer
$29.1K
15.4K sh · $1.89
Own -4%
-
Exercise·M
Kendra Adams KEY
Chief Financial Officer
$0
30.9K sh
Own +8%
-
Grant·A
Chief Scientific Officer
$0
240.0K sh
Own +242%
-
Other·F
Chief People Officer
$3.3K
1.7K sh · $1.89
Own -1%
-
Exercise·M
Chief People Officer
$0
5.0K sh
Own +2%
-
Grant·A
Chief People Officer
$0
200.0K sh
Own +184%
-
Grant·A
Andrew Hirsch KEY
President & CEO
$0
700.0K sh
Own +165%
-
Grant·A
Chief Medical Officer
$0
240.0K sh
Own +153%
-
Grant·A
Chief Accounting Officer
$0
57.0K sh
Own +313%
-
Other·F
Chief Business Officer
$3.3K
1.7K sh · $1.89
Own -1%
-
Exercise·M
Chief Business Officer
$0
5.0K sh
Own +2%
-
Grant·A
Chief Business Officer
$0
200.0K sh
Own +186%
-
Other·F
Kendra Adams KEY
Chief Financial Officer
$3.5K
1.9K sh · $1.89
Own -0%
-
Exercise·M
Kendra Adams KEY
Chief Financial Officer
$0
3.8K sh
Own +1%
-
Grant·A
Kendra Adams KEY
Chief Financial Officer
$0
240.0K sh
Own +148%
-
Sell·S
Chief Medical Officer
$22.2K
10.0K sh · $2.22
Own -6%
-
Grant·A
Director
$14.5K
7.5K sh · $1.93
Own +13%
-
Grant·A
Director
$11.5K
6.0K sh · $1.93
Own +4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Kenneth Carl Anderson | Exercise M | 1.1K | $0 |
| Jun 1, 2026 | Kenneth Carl Anderson | Exercise M | 1.1K | $2.3K |
| Apr 1, 2026 | Donna Roy Grogan | Grant A | 5.4K | $14.5K |
| Apr 1, 2026 | Kenneth Carl Anderson | Grant A | 4.3K | $11.5K |
| Feb 15, 2026 | Andrew Hirsch KEY | Other F | 9.1K | $17.1K |
| Feb 15, 2026 | Andrew Hirsch KEY | Exercise M | 20.4K | $0 |
| Feb 14, 2026 | Paige Mahaney | Other F | 2.4K | $4.6K |
| Feb 14, 2026 | Paige Mahaney | Exercise M | 7.0K | $0 |
| Feb 14, 2026 | Kelly Schick | Other F | 7.3K | $13.7K |
| Feb 14, 2026 | Kelly Schick | Exercise M | 20.9K | $0 |
| Feb 14, 2026 | Andrew Hirsch KEY | Other F | 39.2K | $74.0K |
| Feb 14, 2026 | Andrew Hirsch KEY | Exercise M | 81.7K | $0 |
| Feb 14, 2026 | Leonard Reyno | Other F | 16.6K | $31.3K |
| Feb 14, 2026 | Leonard Reyno | Exercise M | 30.9K | $0 |
| Feb 14, 2026 | Mark Mossler | Other F | 3.3K | $6.2K |
| Feb 14, 2026 | Mark Mossler | Exercise M | 9.4K | $0 |
| Feb 14, 2026 | Scott N Boyle | Other F | 7.3K | $13.7K |
| Feb 14, 2026 | Scott N Boyle | Exercise M | 20.9K | $0 |
| Feb 14, 2026 | Kendra Adams KEY | Other F | 15.4K | $29.1K |
| Feb 14, 2026 | Kendra Adams KEY | Exercise M | 30.9K | $0 |
| Feb 13, 2026 | Paige Mahaney | Grant A | 240.0K | $0 |
| Feb 13, 2026 | Kelly Schick | Other F | 1.7K | $3.3K |
| Feb 13, 2026 | Kelly Schick | Exercise M | 5.0K | $0 |
| Feb 13, 2026 | Kelly Schick | Grant A | 200.0K | $0 |
| Feb 13, 2026 | Andrew Hirsch KEY | Grant A | 700.0K | $0 |
| Feb 13, 2026 | Leonard Reyno | Grant A | 240.0K | $0 |
| Feb 13, 2026 | Mark Mossler | Grant A | 57.0K | $0 |
| Feb 13, 2026 | Scott N Boyle | Other F | 1.7K | $3.3K |
| Feb 13, 2026 | Scott N Boyle | Exercise M | 5.0K | $0 |
| Feb 13, 2026 | Scott N Boyle | Grant A | 200.0K | $0 |
| Feb 13, 2026 | Kendra Adams KEY | Other F | 1.9K | $3.5K |
| Feb 13, 2026 | Kendra Adams KEY | Exercise M | 3.8K | $0 |
| Feb 13, 2026 | Kendra Adams KEY | Grant A | 240.0K | $0 |
| Jan 16, 2026 | Leonard Reyno | Sell S | 10.0K | $22.2K |
| Jan 2, 2026 | Donna Roy Grogan | Grant A | 7.5K | $14.5K |
| Jan 2, 2026 | Kenneth Carl Anderson | Grant A | 6.0K | $11.5K |
About CCCC insider trading
This page tracks insider transactions for C4 Therapeutics, Inc. (CCCC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.